Newcastle University Confidence in Concept 2014

Lead Research Organisation: Newcastle University
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Tan GJS (2019) Blood-borne biomarkers of osteosarcoma: A systematic review. in Pediatric blood & cancer

publication icon
Steele HE (2017) Monitoring clinical progression with mitochondrial disease biomarkers. in Brain : a journal of neurology

publication icon
Silipo M (2015) Deregulation of splicing factors and breast cancer development. in Journal of molecular cell biology

publication icon
Pearce SHS (2021) MANAGEMENT OF ENDOCRINE DISEASE: Residual adrenal function in Addison's disease. in European journal of endocrinology

publication icon
Napier C (2020) Natural History of Adrenal Steroidogenesis in Autoimmune Addison's Disease Following Diagnosis and Treatment. in The Journal of clinical endocrinology and metabolism

publication icon
Mahdi A (2018) What drives development of HCC in non-cirrhotic NAFLD? in Journal of Hepatology

 
Description BH172788 - BRC Muscle and Ageing Science Study
Amount £24,891 (GBP)
Funding ID PDB050 
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 09/2017 
End 03/2019
 
Description BH174433 - BRC Muscle Ageing Sarcopenia Study_Lifecourse (MASS): Establishing a life course cohort - diagnosis and treatment of sarcopenia
Amount £227,235 (GBP)
Funding ID BH174433 
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 06/2018 
End 05/2021
 
Description BRC Chronic Cognitive Impairment in Cholestatic Liver Disease: Impact, Pathogenesis & Treatment
Amount £262,788 (GBP)
Funding ID MJ/ML/1217 - PDB064 
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 03/2018 
End 02/2020
 
Description Changing network interactions in models of medically refractory epilepsy
Amount £381,251 (GBP)
Funding ID MR/R005427/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description Cl-out: a novel cooperative-optogenetic strategy to control neuronal chloride
Amount £594,635 (GBP)
Funding ID BB/P019854/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2017 
End 10/2023
 
Description Comparison of mitochondrial bioenergetic analysis techniques for Chronic Fatigue Syndrome / Myalgic Encephalomyelitis diagnosis
Amount £21,305 (GBP)
Organisation ME Association 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2015 
End 09/2015
 
Description Detection and Isolation of Circulatory Tumour Cells from Sarcome Patients
Amount £65,427 (GBP)
Funding ID 30015.088.043/PA/IXS 
Organisation The JGW Patterson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2015 
End 06/2017
 
Description Determining the role of TLE3 in beta-cell identity and fate conversion
Amount £9,792 (GBP)
Funding ID 16/0005434 
Organisation Diabetes UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2016 
End 08/2017
 
Description Developing techniques to decrease 'pro-cancer' versions of HER2 in breast cancer cells
Amount £22,000 (GBP)
Organisation Gateshead Health NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 07/2016 
End 06/2017
 
Description Development of pre-clinical 3D models of liver cancer to test novel therapies
Amount £80,000 (GBP)
Organisation W. E. Harker Foundation 
Sector Private
Country United Kingdom
Start 03/2020 
 
Description Do the levels of deoxythioguanosine (dTG) in DNA of Autoimmune Hepatitis (AIH) patients with azathioprine correlate with clinica
Amount £17,504 (GBP)
Organisation Newcastle upon Tyne Hospitals NHS Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 05/2017
 
Description EIT Health: 18427 Vitality
Amount £300,000 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2016 
End 12/2018
 
Description EPSRC IAA Phase 2: Exploiting the translational potential of bioinformatics driven diagnostics development
Amount £82,852 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 04/2016 
End 03/2017
 
Description Evaluating the HER2 status: developing assays to measure different versions of HER2 in breast cancer cells
Amount £33,897 (GBP)
Organisation Royal Victoria Infirmary 
Sector Hospitals
Country United Kingdom
Start 06/2016 
End 03/2018
 
Description HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren's Syndrome (pSS) towards improved stratification, treatment and health policy making
Amount £10,000,000 (GBP)
Funding ID 731944 - HarmonicSS - H2020-SC1-2016-2017/H2020-SC1-2016-RTD 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2017 
End 06/2020
 
Description HUNTER: Hepatocellular Carcinoma Expediter Network
Amount £5,000,000 (GBP)
Funding ID C9380/A28223 & A26813 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2018 
End 11/2023
 
Description HUNTER: Hepatocellular Carcinoma Expediter Network
Amount £736,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2019 
 
Description Investigating abnormalities in AMPK activation and mitochondrial function in primary skeletal muscle cell cultures from patients with ME/CFS
Amount £85,518 (GBP)
Organisation ME Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
End 12/2019
 
Description Investigating the clinical implication(s) of HER2 varients in breast cancer
Amount £73,620 (GBP)
Organisation Susan Channon Breast Cancer Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2018 
End 08/2021
 
Description Liver Investigation: Testing Marker Unitity in Steatohepatitis (LITMUS)
Amount £3,321,093 (GBP)
Funding ID 777377 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2017 
End 10/2022
 
Description MICA-Molecular drivers of fibrosis at the hepatic epithelial-mesenchymal barrier
Amount £1,871,277 (GBP)
Funding ID MR/R023026/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2019 
End 01/2024
 
Description MICA: Exploring a new perspective on the mechanism of action of Glucokinase Activators in liver, a preclinical study
Amount £606,933 (GBP)
Funding ID MR/P002854/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2017 
End 01/2021
 
Description MICA: Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy (AIMM)
Amount £1,684,631 (GBP)
Funding ID MR/R006458/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 10/2022
 
Description Mechanisms of chronic liver disease associated with hepatitis C virus genotype 3 infection
Amount £80,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description Mitochondrial Proliferators
Amount £218,000 (GBP)
Organisation Morningside Venture Capital 
Sector Private
Country China
Start 08/2019 
 
Description Mitochondrial Proliferators
Amount £395,088 (GBP)
Organisation Morningside Venture Capital 
Sector Private
Country China
Start 06/2016 
 
Description Modelling inflammation and fibrosis using precision cut lung slices
Amount £265,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start  
 
Description Neutrophils as drivers of hepatocellular carcinoma progression - predictive biomarker and target for therapeutic intervention?
Amount £140,553 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description OCA on cognitive Symptoms
Amount £22,169 (GBP)
Organisation Intercept Pharmaceuticals 
Sector Private
Country United States
Start 12/2014 
End 11/2017
 
Description Obetichololic Acid for Cognitive Symptoms: The OACS Trial Programme
Amount £2,500,000 (GBP)
Organisation Intercept Pharmaceuticals 
Sector Private
Country United States
Start 04/2020 
End 12/2024
 
Description PCLS Study
Amount £104,598 (GBP)
Funding ID 43088140 
Organisation Boehringer Ingelheim 
Sector Private
Country Germany
Start 06/2018 
End 05/2019
 
Description PCLS study
Amount £94,875 (GBP)
Organisation AstraZeneca 
Department MedImmune
Sector Private
Country United Kingdom
Start  
 
Description PCLS study
Amount £43,480 (GBP)
Organisation Enleofen 
Sector Private
Country Singapore
Start  
 
Description PCLS study - Pilot
Amount £16,038 (GBP)
Organisation Nuformix 
Sector Private
Country United Kingdom
Start  
 
Description RESi-Sense PRF - IDRIS System: proof of concept and exploration of commercialisation routes
Amount £49,967 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 05/2016 
End 05/2017
 
Description Studentship (50%) Anna-Lena Ditrich
Amount £28,398 (GBP)
Organisation Royal Victoria Infirmary 
Sector Hospitals
Country United Kingdom
Start 03/2015 
End 09/2016
 
Description Targeting RAS pathway medicated chemo-resistance in acute lymphoblastic leukaemia
Amount £62,172 (GBP)
Funding ID 30015.088.055/PA/IXS 
Organisation The JGW Patterson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2016 
End 02/2017
 
Description Testing the hypothesis that LDAA reduces UV-mediated damage to mitochondrial and nuclear DNA compared to AZA
Amount £44,621 (GBP)
Funding ID 30015.088.0789/PA/IXS 
Organisation The JGW Patterson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 08/2018
 
Description Testing the hypothesis that LDAA reduces UV-mediated damage to mitochondrial and nuclear DNA compared to AZA
Amount £44,621 (GBP)
Organisation The JGW Patterson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2017 
End 05/2018
 
Description Towards Targeting Neutrophils in Hepatocellular Carcinoma
Amount £140,551 (GBP)
Funding ID C18342/A24691 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 02/2021
 
Description Towards targeting neutrophils in hepatocellular carcinoma
Amount £941,943 (GBP)
Funding ID A23390 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 02/2022
 
Description Virtual reality intervention for children and adults with autism and anxiety
Amount £44,872 (GBP)
Organisation United Kingdom Research and Innovation 
Department Northern Accelerator
Sector Charity/Non Profit
Country United Kingdom
Start 06/2019 
End 06/2020
 
Title Cl-out: A novel optogenetic protein for removing chloride from neurons 
Description The development of a novel light-sensitive membrane protein that, when activated, drives chloride out of cells. The usefulness of this is that there is considerable evidence that a primary pathology in many types of epilepsy arises from a failure to regulate neuronal chloride levels, leading to the build up of chloride inside cells. Our novel strategy allowed a direct test of this hypothesis and may provide therapeutic avenues. 
IP Reference GB1601008.4 
Protection Patent granted
Year Protection Granted 2016
Licensed No
Impact This work continues to be a major focus of Dr Trevelyan's laboratory. They will continue this work in parallel with the CANDO project, and aim to bring in further research funds to test the strategy for modulating neuronal activity, and in particular epileptic activity, in more sophisticated animal models, including in vivo.